Basic Information
| LncRNA/CircRNA Name | NONHSAT141924 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Paclitaxel (PTX) | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot, Microarray etc. |
| Sample | primary breast infiltrating ductal carcinoma tissues and their paired normal tissues,cell lines (BT-549, MDA-MB-231, Hs-578T, ZR-75-30, T-47D and MCF-7) |
| Expression Pattern | up-regulated |
| Function Description | NONHSAT141924 was most closely associated with paclitaxel (PTX)-resistant phenotype. To further explore the mechanism by which LncRNA NONHSAT141924 contributes to PTX-resistant characteristics, LncRNA NONHSAT141924 was transfected into MCF-7 breast cancer cell line. Overexpression of LncRNA NONHSAT141924 significantly reduced MCF-7 cell survivability through modulation of p-CREB/Bcl-2 apoptosis signaling pathway, one of the major pathways participated in LncRNAs-mediated chemotherapy resistance. |
| Pubmed ID | 32284761 |
| Year | 2020 |
| Title | LncRNA NONHSAT141924 promotes paclitaxel chemotherapy resistance through p-CREB/Bcl-2 apoptosis signaling pathway in breast cancer. |
External Links
| Links for NONHSAT141924 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |